AMEX · NRXS
NeurAxis, Inc.
$7.55-$0.02 (-0.26%)
NeurAxis, Inc.’s quoted price sits in the upper half of its reported 52-week range, 19.08% below the high.
Loading market information…
NASDAQ · NXL · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Nexalin Technology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.71% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Nexalin Technology, Inc.’s next earnings report is currently expected on Nov 13, 2026, with estimated earnings per share of -$2.91. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Nexalin Technology, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Nexalin Technology, Inc. operates as a medical device firm specializing in the creation and advancement of neurostimulation therapies for mental health conditions in both the United States and China. The company commercializes its primary product, the Nexalin Device, which provides a non-invasive and drug-free treatment for anxiety and insomnia. This device functions by emitting a proprietary frequency-based waveform designed to elicit a beneficial response from mid-brain structures associated with various psychological disorders. Furthermore, Nexalin Technology is currently developing "Generation 2," a new medical device undergoing clinical trials. This future product aims to address a broader spectrum of health issues, including opiate addiction, persistent pain, Alzheimer's disease, and dementia. The company was founded in 2021 and has its headquarters in Houston, Texas.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 13, 2025 | -$0.150.0% vs estimate | $41.00K0.0% vs estimate |
|---|
| Q4 2024 | Mar 14, 2025 | -$0.28+92.22% vs estimate | $30.00K0.0% vs estimate |
|---|
| Q3 2024 | Nov 8, 2024 | -$0.23-91.67% vs estimate | $36.00K+20.0% vs estimate |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$7.55-$0.02 (-0.26%)
NeurAxis, Inc.’s quoted price sits in the upper half of its reported 52-week range, 19.08% below the high.
$2.54-$0.07 (-2.68%)
Enlivex Therapeutics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 99.42% below the high.
$8.80+$0.38 (+4.51%)
Harvard Bioscience, Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.38% below the high.
$1.05-$0.01 (-0.94%)
Inspira Technologies OXY B.H.N. Ltd.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$3.86-$0.09 (-2.28%)
SCYNEXIS, Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.68% below the high.
$0.58-$0.01 (-1.15%)
Retractable Technologies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 37.67% below the high.
$1.72-$0.19 (-9.95%)
Modular Medical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.79% below the high.
$4.40+$0.45 (+11.39%)
CollPlant Biotechnologies Ltd.’s quoted price sits in the lower half of its reported 52-week range, 80.79% below the high.
